Marca Nominativa depositada no INPI em 26/01/2024 por Vyriad, Inc., processo nº 501783466, nas classes 05, 42, 44. Registro em vigor até 26/01/2034.
| Número do processo | 501783466 |
|---|---|
| Situação | Registro de marca em vigor (Madri) |
| Apresentação | Nominativa |
| Natureza | Madri Produto/Serviço |
| Data do depósito | 26/01/2024 |
| Data da concessão | 02/09/2025 |
| Vigência até | 26/01/2034 |
| Titular | Vyriad, Inc. |
| CNPJ/CPF do titular | — |
| UF · País | — · US |
Medicinal preparations for the treatment of infectious diseases; pharmaceutical preparations for providing stem cell therapy; Pharmaceuticals, namely, bio-pharmaceuticals for the treatment of cancer; stem cells for medical use for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; medicinal preparations for use in oncology; pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely, cancer and cardiovascular diseases and heritable genetic diseases; cellular pharmaceutical preparations for use in oncology and cardio-vascular diseases; living tissue in the nature of chimeric antigen receptor (CAR-T) cells for medical use for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; pharmaceutical preparations for use in oncology; all of the foregoing to exclude infectious diseases.;
Development of therapeutics and cell therapies.;
Medical and scientific research and development in the fields of cancer treatment and oncolytic virotherapy; research and development of bio-pharmaceuticals for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; medical and scientific research in the fields of genetics and oncology; research and development of technology in the fields of stem cells and stem cell therapy for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; development of genetic therapies and chimeric antigen receptor cell (CAR-T) cell therapies for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; scientific research and development of cell therapies, namely, chimeric antigen receptor T-cells (CAR-T) to cure solid tumor cancers and other cancers; medical and scientific research services in the fields of genetics, cell therapy, oncology, immuno-oncology; all of the foregoing to exclude infectious diseases.;
Cancer treatment medical services; oncolytic virotherapy medical services; stem cell therapy services; medical services in the field of oncology; medical services, namely, cellular immunotherapy treatments utilizing chimeric antigen receptor T-cells for use in treating disease, namely, the treatment of cancer.;
Receba um e-mail a cada novo despacho publicado na RPI para o processo 501783466 — exigência, oposição, deferimento, prazo de pagamento — e quando alguém depositar uma marca parecida.
Monitorar esta marca Ver marcas parecidas5 despacho(s) publicado(s) na Revista da Propriedade Industrial.